Search results for "FLOX"

showing 10 items of 109 documents

Synthesis, Structural Analysis, Fiber Formation and Preliminary Anticancer Characterization of the Organotin Polyether from Dibutyltin Dichloride and…

2012

The organotin polyether derived from reaction of dibutyltin dichloride and 2,5-dimethyl-3-hexyne-2,5-diol was rapidly synthesized employing classical interfacial polymerization in 65% yield and a chain length of 360 units. IR results are consistent with the polyether structure. Bands characteristic of the formation of the Sn-O are present and bands characteristic of the Sn-Cl are absent. F MALDI MS results in the low mass range gives ion fragment clusters to five units. Isotopic abundance matches for tin are consistent with its presence in these ion fragment clusters. In the high mass range ion fragment clusters to greater than 300 units are found. The products offer outstanding inhibition …

AMPICILLINMALDI MSORGANOMETALLIC POLYMERSanomalous fiber formationANTIVIRAL ACTIVITYSettore CHIM/05 - Scienza E Tecnologia Dei Materiali PolimericiCONTAINING POLYMERSOrganotin polyetherCONDENSATIONtin-containing polymerF MALDI MSSettore CHIM/03 - Chimica Generale E InorganicaNORFLOXACININTERFACIAL TECHNIQUEanticancer drugdibutyltin dichlorideMATRIXPOLYESTERS25-dimethyl-3-hexyne-25-diol
researchProduct

Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011

2013

Introduction: Nosocomial pneumonia remains an important cause of mortality and morbidity worldwide. Surveillance programs play an important role in the identification of common etiologic agents and local patterns of antimicrobial resistance. Methodology: In this study we determined the frequency and antimicrobial susceptibility of pathogens isolated from patients with nosocomial pneumonia during 2009 to 2011. Results: A total of 642 bacteria were isolated from 516 suspected samples. Acinetobacter baumannii (21.1%, n = 136), was the commonest isolated pathogen followed by Pseudomonas aeruginosa (17.4%, n = 112) , Staphylococcus aureus (15.8%, n = 102) and enterococci (8.4% n = 54). The most …

Acinetobacter baumanniiSettore MED/07 - Microbiologia E Microbiologia ClinicaPenicillanic AcidDrug resistanceIranmedicine.disease_causechemistry.chemical_compoundLevofloxacinDrug Resistance Multiple BacterialPrevalenceRespiratory Tract InfectionsPolymyxin BCross InfectionbiologyCeftriaxoneGeneral MedicineHospitalsAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPiperacillin Tazobactam Drug CombinationPseudomonas aeruginosaCeftriaxonemedicine.drugMethicillin-Resistant Staphylococcus aureusStaphylococcus aureusMicrobial Sensitivity TestsMicrobiologyTazobactamMicrobiologyAntibiotic resistanceAcinetobacter baumanniiiVirologymedicinePneumonia BacterialHumansTehran hospitalsGram-Positive Bacterial InfectionsPiperacillindrug resistancebusiness.industryPseudomonas aeruginosanosocomial pneumoniaSputumbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationchemistrynosocomial pneumonia; drug resistance; Acinetobacter baumanniii; Pseudomonas aeruginosa; Tehran hospitalsLinezolidParasitologybusinessGram-Negative Bacterial Infections
researchProduct

High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors

2016

International audience; Inhibitors of uridine diphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC, which catalyses the first, irreversible step in lipid A biosynthesis) are a promising new class of antibiotics against Gram-negative bacteria. The objectives of the present study were to: (i) compare the antibiotic activities of three LpxC inhibitors (LPC-058, LPC-011 and LPC-087) and the reference inhibitor CHIR-090 against Gram-negative bacilli (including MDR and XDR isolates); and (ii) investigate the effect of combining these inhibitors with conventional antibiotics.MethodsMICs were determined for 369 clinical isolates (234 Enterobacteriaceae and 135 non-fermentati…

Acinetobacter baumanniiThreonine0301 basic medicineMicrobiology (medical)Klebsiella pneumoniaemedicine.drug_class030106 microbiologyAntibioticsMicrobial Sensitivity TestsHydroxamic Acidsmedicine.disease_causebeta-LactamasesAmidohydrolasesMicrobiology03 medical and health sciencesBacterial ProteinsEnterobacteriaceae[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance Multiple BacterialGram-Negative BacteriaEscherichia colipolycyclic compoundsmedicineHumansPharmacology (medical)Enzyme InhibitorsOriginal ResearchPharmacologybiologyPseudomonas aeruginosaEnterobacteriaceae Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycosesAntimicrobialbiology.organism_classificationEnterobacteriaceaeAnti-Bacterial Agents3. Good healthAcinetobacter baumanniiCiprofloxacinKlebsiella pneumoniae[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesAmikacinPseudomonas aeruginosalipids (amino acids peptides and proteins)medicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Pefloxacine mesilate- and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation.

1995

The entrapment of fluoroquinolones, perfloxacine mesilate (PFX) and ofloxacin (OFX), in polyalkylcyanoacrylate (PECA) nanoparticles could offer some advantages for their biological application; for examples, increasing their bioavailability, controlling the drug time-release in blood, and reducing the formation of bacterial resistance. To load these two drugs in PECA polymeric bulk, the incorporation or adsorption method was performed. These two methods were capable of influencing nanoparticle size, molecular weight, release profile, and drug–polymer association. The incorporation method, particularly for the OFX system, achieved PECA nanoparticle suspensions with a mean size value three ti…

Active ingredientOfloxacinTime FactorsMolecular StructureChemistryPharmaceutical ScienceNanoparticleBiological AvailabilityNanotechnologyDosage formPefloxacinBioavailabilityChemical engineeringPharmaceutical PreparationsmedicineParticle sizeOfloxacinDrug carrierMathematicsmedicine.drugAntibacterial agentJournal of pharmaceutical sciences
researchProduct

Pefloxacin in the Antibacterial Treatment of Immunodepressed Patients

1990

Pefloxacin 800 to 1200 mg daily was given for 3 to 20 days, orally or intravenously, to 84 immunocompromised patients. Five patients dropped out because of side effects and 2 for other causes. Treatment efficacy was evaluated in 77 patients, 43 men and 34 women, aged 18 to 80 years. Immunodepression resulted from malignancy in 46 patients, LAS/ARC or AIDS in 28, and from unknown causes in 3. Fifty-eight patients had documented infections (respiratory-tract infections 29, urinary-tract infections 13, septicemia 10, other 6) and 19 had a fever of unknown origin (FUO). Cure or significant improvement of symptoms was achieved in 81% of patients with documented infections and in 74% of patients …

Adult0301 basic medicinemedicine.medical_specialty030106 microbiologyAIDS-related complexMalignancyPefloxacin03 medical and health sciencesGastrointestinal disturbances0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)NeoplasmsInternal medicineImmune ToleranceHumansMulticenter Studies as TopicMedicinePharmacology (medical)Fever of unknown originAgedAged 80 and overPharmacologyAcquired Immunodeficiency Syndromebusiness.industryBacterial InfectionsMiddle Agedmedicine.diseaseRashPefloxacinTreatment efficacyInfectious DiseasesOncology030220 oncology & carcinogenesismedicine.symptombusinessmedicine.drugJournal of Chemotherapy
researchProduct

Gentamicin, norfloxacin and lysozyme concentration in human tears: in vivo and in vitro study

1992

Hen's egg lysozyme (HEL) activity was measured in vitro with gentamicin and norfloxacin by a turbidimetric technique. Gentamicin at the concentration of 10(-3) M inhibited HEL activity by 39%, while 10(-3) M norfloxacin did not affect HEL activity. However, an in vivo study in healthy persons did not show any significant statistical difference in tear lysozyme activity when 0.3% gentamicin or 0.3% norfloxacin were topically applied.

AdultMaleAdolescentEgg lysozymechemical and pharmacologic phenomenaIn Vitro TechniquesgentamicinPharmacologyMicrobiologyCorneachemistry.chemical_compoundIn vivomedicineHumansIn vitro studyheterocyclic compounds[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganslysozymeNorfloxacinocular surface[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyChemistryhemic and immune systemsGeneral Medicinebiochemical phenomena metabolism and nutritioninfectionIn vitroOphthalmology[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansTearsTearsMuramidaseGentamicinGentamicinsOphthalmic SolutionsLysozyme[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyNorfloxacinmedicine.drugActa Ophthalmologica
researchProduct

Re: Antimicrobial Resistance in More Than 100,000 Escherichia coli Isolates According to Culture Site and Patient Age, Gender, and Location

2011

ABSTRACT Escherichia coli and the antimicrobial pressure exerted on this microorganism can be modulated by factors dependent on the host. In this paper, we describe the distribution of antimicrobial resistance to amikacin, tobramycin, ampicillin, amoxicillin clavulanate, cefuroxime, cefoxitin, cefotaxime, imipenem, ciprofloxacin, fosfomycin, nitrofurantoin, and trimetoprim-sulfametoxazole in more than 100,000 E. coli isolates according to culture site and patient age, gender, and location. Bayesian inference was planned in all statistical analysis, and Markov chain Monte Carlo simulation was employed to estimate the model parameters. Our findings show the existence of a marked difference in…

AdultMaleCefotaximeAdolescentmedicine.drug_classUrologyAntibioticsCefotaximeDrug resistanceFosfomycinBiologymedicine.disease_causeEpidemiology and SurveillanceMicrobiologyYoung AdultAntibiotic resistanceFosfomycinCiprofloxacinPatient ageDrug Resistance Multiple BacterialEscherichia coliHumansMedicinePharmacology (medical)ChildAmikacinEscherichia coliEscherichia coli InfectionsAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologybusiness.industryInfantMiddle AgedAntimicrobialAnti-Bacterial AgentsImipenemInfectious DiseasesNitrofurantoinAmikacinChild PreschoolTobramycinAmpicillinFemalebusinessmedicine.drugJournal of Urology
researchProduct

Topical Antibiotic, Antifungal, and Antiseptic Solutions Decrease Ciliary Activity in Nasal Respiratory Cells

2002

This study was designed to investigate whether topical solutions, as they are used in the treatment of selected cases of rhinosinusitis, influence nasal mucociliary clearance. The objective of this study was to evaluate the effects of the following topical solutions on the ciliary beat frequency (CBF) of nasal respiratory cells: ofloxacin as an antibiotic; Betadine and hydrogen peroxide (H2O2) as antiseptic; and amphotericin B, itraconazole, and clotrimazole as antifungal solutions. Differences are described between effects of each of these substances and we clarify whether ciliotoxic effects are dose dependent and if they can be reduced or eliminated by diluting the concentration of the a…

AdultMaleOfloxacinAntifungal AgentsMucociliary clearanceItraconazolemedicine.drug_classAntibioticsPharmacologySensitivity and SpecificityMicrobiology03 medical and health sciences0302 clinical medicineAntisepticReference ValuesAmphotericin BAmphotericin BmedicineHumansClotrimazoleRespiratory system030223 otorhinolaryngologyPovidone-IodineCells CulturedDose-Response Relationship Drugbusiness.industryClotrimazoleNasal MucosaOtorhinolaryngologyMucociliary Clearance030220 oncology & carcinogenesisAnti-Infective Agents LocalFemaleOfloxacinItraconazolebusinessmedicine.drugAmerican Journal of Rhinology
researchProduct

Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam Three Times a Day: A Randomized Controlled Multicenter Trial in Patients with…

2004

A prospective, randomized, controlled multicenter trial was performed to evaluate the efficacy and safety of once-daily oral monotherapy with 500 mg levofloxacin in comparison with 4.5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia. Low risk was defined by oral temperatureor = 38.5 degrees C on one occasion oror = 38.0 degrees C twice within 24 hours and granulocytopeniaor = 500/microL for less than 10 days. The primary end point was defined as defervescence after 72 hours followed by at least 7 afebrile days. Secondary end points were overall response, time to defervescence, survival on day 30, and toxicity. Thirty-four episodes were included. Fever o…

AdultMaleOfloxacinTazobactammedicine.medical_specialtyNeutropeniaFeverAdministration OralPenicillanic AcidAntineoplastic AgentsLevofloxacinNeutropeniaFever of Unknown OriginTazobactamDrug Administration ScheduleImmunocompromised HostLevofloxacinNeoplasmsInternal medicineMulticenter trialHumansMedicineProspective StudiesAgedAntibacterial agentPiperacillinbusiness.industryBacterial InfectionsHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomePiperacillin/tazobactamDrug Therapy CombinationFemaleDisease SusceptibilitySafetybusinessFebrile neutropeniaPiperacillinmedicine.drugInternational Journal of Hematology
researchProduct

Can CAP guideline adherence improve patient outcome in internal medicine departments?

2008

The impact of compliance with Italian guidelines on the outcome of hospitallised community-acquired pneumonia (CAP) in internal medicine departments was evaluated. All Fine class IV or V CAP patients were included in this multicentre, interventional, before-and-after study, composed of three phases: 1) a retrospective phase (RP; 1,443 patients); 2) a guideline implementation phase; and 3) a prospective phase (PP; 1,404 patients). Antibiotic prescription according to the guidelines increased significantly in the PP. The risk of failure at the end of the firstline therapy was significantly lower in the PP versus the RP (odds ratio (OR) 0.83, 95% confidence interval (CI) 0.69-1.00), particular…

AdultMalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtycommunity acquired-pneumonia guideline internal medicineadherenceCritical Caremedicine.drug_classAntibioticsPopulationCommunity-acquired pneumoniaLevofloxacinInternal medicineInternal MedicinemedicineHumansProspective StudieseducationAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryPneumoniaOdds ratioGuidelineMiddle Agedmedicine.diseaseConfidence intervalCommunity-Acquired InfectionsPneumoniaTreatment OutcomeItalyFemaleGuideline Adherencebusinessmedicine.drugEuropean Respiratory Journal
researchProduct